Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms

被引:12
作者
Taboada, Rodrigo [1 ]
Claro, Laura [2 ]
Felismino, Tiago [1 ]
de Jesus, Victor Hugo [1 ]
Barros, Milton [1 ]
Riechelmann, Rachel P. [1 ]
机构
[1] AC Camargo Canc Ctr, Dept Med Oncol, BR-01509010 Sao Paulo, Brazil
[2] AC Camargo Canc Ctr, Dept Pathol, Sao Paulo, Brazil
关键词
grade 3 neuroendocrine tumor; high-grade neuroendocrine neoplasms; molecular landscape; neuroendocrine carcinoma; CARCINOMAS; ETOPOSIDE; TUMORS; G3;
D O I
10.1111/jne.13099
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The 2019 Word Health Organization (WHO) subclassified grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) into neuroendocrine carcinoma (NEC) or tumours (G3 NET) based on morphology and proliferation. Yet, few data exist on molecular profiles for G3 NEN. We compared clinicopathological and molecular characteristics of these two groups. We retrospectively reviewed consecutive G3 GEP NEN patients and had their tumour tissues reviewed, reclassified as per the WHO 2019, and analyzed by a next-generation sequencing (NGS) panel. Between 2000 and 2019, 43 patients had pathology revision: 29 (67%) were NEC and 14 (33%) were G3 NET, with a 23% change in diagnosis. Median overal survival for G3 NET and NEC patients was 55.6 and 11.9 months, respectively (hazard ratio = 2.78 [95% confidence interval = 1.09-7.11], p = .042), which was confirmed by an adjusted analysis (hazard ratio = 2.90 NEC vs. G3 NET; p = .03). NGS was performed in 32 cases: 21 NEC and 11 G3 NET. Mutations in RB1 and PTEN were exclusively encountered in NEC. Median tumour mutational burden was 5 (0-67) mutations per megabase in NEC and 4.5 (0-9) among G3 NET. Microsatellite instability was found in 3 (14.3%) NEC cases. In conclusion, pathology revision is essential to estimate prognosis and therapeutic plan. G3 GEP NEN generally harbour low tumor mutation burden and fewer actionable mutations, but 14% of NEC cases were microsatellite unstable and could benefit from immune checkpoint inhibitors.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms
    Uhlig, Johannes
    Nie, James
    Gibson, Joanna
    Cecchini, Michael
    Stein, Stacey
    Lacy, Jill
    Kunz, Pamela
    Kim, Hyun S.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [42] Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms
    Huang, Pao-Yuan
    Tsai, Kai-Lung
    Liang, Chih-Ming
    Tai, Wei-Chen
    Rau, Kun-Ming
    Wu, Keng-Liang
    Huang, Chao-Cheng
    Chuah, Seng-Kee
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2018, 34 (11) : 650 - 656
  • [43] Neuroendocrine Neoplasms of the Gastroenteropancreatic System: Pathology and Classification
    Anlauf, M.
    HORMONE AND METABOLIC RESEARCH, 2011, 43 (12) : 825 - 831
  • [44] Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms
    Sigel, Carlie S.
    CANCER CYTOPATHOLOGY, 2018, 126 (12) : 980 - 991
  • [45] Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms
    La Rosa, Stefano
    ENDOCRINE PATHOLOGY, 2021, 32 (02) : 245 - 257
  • [46] Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value
    Yin, L.
    Wang, R.
    Ma, X.
    Jiang, K.
    Hu, Y.
    Zhao, X.
    Zhang, L.
    Wang, Z.
    Long, T.
    Lu, M.
    Li, J.
    Sun, Y.
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [47] Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience
    Kanakasetty, Govind Babu
    Dasappa, Loknatha
    Lakshmaiah, Kuntegowdanahalli Chinnagiriyappa
    Kamath, Mangesh
    Jacob, Linu Abraham
    Mallekavu, Suresh Babu
    Rajeev, Lakkavalli Krishnappa
    Haleshappa, Rudresha Antapura
    Nagendrappa, Lokesh Kadabur
    Saldanha, Smitha Carol
    Kumar, Rekha V.
    JOURNAL OF ONCOLOGY, 2016, 2016
  • [48] Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
    Puccini, Alberto
    Poorman, Kelsey
    Salem, Mohamed E.
    Soldato, Davide
    Seeber, Andreas
    Goldberg, Richard M.
    Shields, Anthony F.
    Xiu, Joanne
    Battaglin, Francesca
    Berger, Martin D.
    Tokunaga, Ryuma
    Naseem, Madiha
    Barzi, Afsaneh
    Iqbal, Syma
    Zhang, Wu
    Soni, Shivani
    Hwang, Jimmy J.
    Philip, Philip A.
    Sciallero, Stefania
    Korn, W. Michael
    Marshall, John L.
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5943 - 5951
  • [49] A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors
    Donadio, Mauro D.
    Brito, Angelo B.
    Riechelmann, Rachel P.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [50] Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms
    Liverani, Chiara
    Bongiovanni, Alberto
    Mercatali, Laura
    Pieri, Federica
    Spadazzi, Chiara
    Miserocchi, Giacomo
    Di Menna, Giandomenico
    Foca, Flavia
    Ravaioli, Sara
    De Vita, Alessandro
    Cocchi, Claudia
    Rossi, Giulio
    Recine, Federica
    Ibrahim, Toni
    ENDOCRINE PATHOLOGY, 2021, 32 (02) : 309 - 317